Načítá se...
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
BACKGROUND: Following a clinical evaluation of deferasirox (Exjade(®)) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, i...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Ferrata Storti Foundation
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2857545/ https://ncbi.nlm.nih.gov/pubmed/19951979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.014696 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|